Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares hit a new 52-week high during trading on Wednesday . The company traded as high as $29.70 and last traded at $29.19, with a volume of 97651 shares. The stock had previously closed at $28.78.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Wolfe Research initiated coverage on Alto Neuroscience in a research note on Friday, May 22nd. They issued an “outperform” rating on the stock. Robert W. Baird cut their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Bank of America initiated coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target on the stock. Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Finally, Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $35.25.

Alto Neuroscience Trading Up 0.9%

The company’s fifty day moving average price is $25.24 and its two-hundred day moving average price is $22.48. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -12.00 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Research analysts expect that Alto Neuroscience, Inc. will post -3.14 earnings per share for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently bought and sold shares of ANRO. Commodore Capital LP grew its holdings in shares of Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after purchasing an additional 900,000 shares during the last quarter. Vestal Point Capital LP lifted its position in Alto Neuroscience by 161.6% during the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares in the last quarter. Perceptive Advisors LLC lifted its position in Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after buying an additional 225,500 shares in the last quarter. Armistice Capital LLC grew its holdings in Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares during the last quarter. Finally, Spruce Street Capital LP grew its holdings in Alto Neuroscience by 494.7% during the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.